{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:14:43Z","timestamp":1793859283016,"version":"4.6.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR077073-01A1"],"award-info":[{"award-number":["K23AR077073-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,17]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n                  <jats:p>Prurigo nodularis (PN) is a chronic skin condition featuring extremely itchy nodules on the skin of the legs, arms and trunk of the body. PN affects approximately 72 per 100 000 people and the severe itch associated with the condition can negatively impact a person\u2019s sleep, work and social life. However, the cause of PN remains unclear.<\/jats:p>\n                  <jats:p>Current understanding of PN is based on imbalances in the immune system leading to widespread inflammation as well as dysregulation of the nerves in the skin. Immune molecules released from T cells [such as interleukin (IL)-4, -13, -31, -17, -22 and -31] increase systemic inflammation and are elevated in people with PN. Activated inflammatory cells (such as mast cells or eosinophils) may also release factors that promote inflammation, itch and neural changes within the skin. Neural dysregulation in PN features a lower density of itch-sensing nerve fibres in the epidermis (upper layer of the skin) and a higher density of itch-sensing nerve fibres in the dermis (lower layer of the skin). Because the pathogenesis of PN is not fully understood, the therapies available for PN have had limited success in reducing itch and nodules.<\/jats:p>\n                  <jats:p>The only drug currently approved for PN in the USA and Europe is dupilumab, an IL-4R\u03b1 inhibitor that blocks signalling through IL-4 and IL-13, which is undergoing post-marketing surveillance. Other new drugs are being assessed in various phases of clinical trials, including nemolizumab, vixarelimab, barzolvolimab, ruxolitinib, abrocitinib, povorcitinib and nalbuphine.<\/jats:p>","DOI":"10.1093\/bjd\/ljae052","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T16:55:28Z","timestamp":1707497728000},"page":"798-810","source":"Crossref","is-referenced-by-count":84,"title":["Prurigo nodularis: new insights into pathogenesis and\u00a0novel therapeutics"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-1298","authenticated-orcid":false,"given":"Viviane","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-2479","authenticated-orcid":false,"given":"Hannah L","family":"Cornman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-6659","authenticated-orcid":false,"given":"Emily","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1515","authenticated-orcid":false,"given":"Shawn G","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology"},{"name":"Maryland Itch Center, University of Maryland School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"2024051712184643900_ljae052-B1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the itch\u2013scratch cycle in prurigo nodularis","volume":"382","author":"Kwatra","year":"2020","journal-title":"N Engl J Med"},{"key":"2024051712184643900_ljae052-B2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","article-title":"Health-related quality of life and economic burden of prurigo nodularis","volume":"86","author":"Whang","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","article-title":"Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients","volume":"37","author":"Weigelt","year":"2010","journal-title":"J Cutan Pathol"},{"key":"2024051712184643900_ljae052-B5","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jaci.2022.02.021","article-title":"Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024051712184643900_ljae052-B6","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3571","article-title":"Analysis of 325 patients with chronic nodular prurigo: clinics, burden of disease and course of treatment","volume":"100","author":"Gr\u00fcndel","year":"2020","journal-title":"Acta Dermato-Venereol"},{"key":"2024051712184643900_ljae052-B7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.1993.01680280049009","article-title":"Mast cells, neutrophils, and eosinophils in prurigo nodularis","volume":"129","author":"Perez","year":"1993","journal-title":"Arch Dermatol"},{"key":"2024051712184643900_ljae052-B8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.jid.2023.04.033","article-title":"A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis","volume":"143","author":"Vasavda","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"2024051712184643900_ljae052-B9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2023.04.015","article-title":"Prevalence of tuberculosis in patients with prurigo nodularis: a multicenter cross-sectional study","volume":"89","author":"Cornman","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clim.2014.01.010","article-title":"Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3","volume":"151","author":"Ashenafi","year":"2014","journal-title":"Clin Immunol"},{"key":"2024051712184643900_ljae052-B12","doi-asserted-by":"crossref","first-page":"632683","DOI":"10.3389\/fmed.2021.632683","article-title":"Causes of pruritus in patients treated with immune checkpoint inhibitors for melanomas or skin carcinomas","volume":"8","author":"Salinas","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024051712184643900_ljae052-B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial","volume":"79","author":"Steinke","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/ced.14722","article-title":"Clinical characteristics and disease burden in prurigo nodularis","volume":"46","author":"Aggarwal","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2024051712184643900_ljae052-B15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","article-title":"Itch: pathogenesis and treatment","volume":"86","author":"Sutaria","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B16","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"2024051712184643900_ljae052-B18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"2024051712184643900_ljae052-B19","doi-asserted-by":"crossref","first-page":"638325","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024051712184643900_ljae052-B20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2024051712184643900_ljae052-B21","doi-asserted-by":"crossref","first-page":"1022889","DOI":"10.3389\/fmed.2022.1022889","article-title":"Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis","volume":"9","author":"Deng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024051712184643900_ljae052-B22","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3702","article-title":"Dermal periostin: a new player in itch of prurigo nodularis","volume":"101","author":"Hashimoto","year":"2021","journal-title":"Acta Dermato-Venereol"},{"key":"2024051712184643900_ljae052-B23","doi-asserted-by":"crossref","first-page":"1011142","DOI":"10.3389\/fmed.2022.1011142","article-title":"Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis","volume":"9","author":"Parthasarathy","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024051712184643900_ljae052-B24","doi-asserted-by":"crossref","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Reports"},{"key":"2024051712184643900_ljae052-B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2023.12.021","article-title":"Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis","author":"Patel","year":"2024  19","journal-title":"J Invest Dermatol"},{"key":"2024051712184643900_ljae052-B26","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","article-title":"Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization","volume":"141","author":"Belzberg","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2024051712184643900_ljae052-B27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jid.2019.08.438","article-title":"IL-17A induces endothelin-1 expression through p38 pathway in prurigo nodularis","volume":"140","author":"Wong","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2024051712184643900_ljae052-B28","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","article-title":"Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis","volume":"142","author":"Sutaria","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2024051712184643900_ljae052-B29","first-page":"111","article-title":"Transcriptional analysis-based alterations affecting neuritogenesis of the peripheral nervous system in psoriasis","volume":"12","author":"Romh\u00e1nyi","year":"2022","journal-title":"Life (Basel)"},{"key":"2024051712184643900_ljae052-B30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/medicines7010004","article-title":"Association between prurigo nodularis and etiologies of peripheral neuropathy: suggesting a role for neural dysregulation in pathogenesis","volume":"7","author":"Hughes","year":"2020","journal-title":"Medicines"},{"key":"2024051712184643900_ljae052-B31","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/brain\/awn093","article-title":"The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology","volume":"131","author":"Devigili","year":"2008","journal-title":"Brain"},{"key":"2024051712184643900_ljae052-B32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jdermsci.2006.12.007","article-title":"Changes in cutaneous sensory nerve fibers induced by skin-scratching in mice","volume":"46","author":"Yamaoka","year":"2006","journal-title":"J Dermatol Sci"},{"key":"2024051712184643900_ljae052-B33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00403-001-0285-8","article-title":"Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin \u2013 an exploration of the cause of neurohyperplasia","volume":"293","author":"Johansson","year":"2002","journal-title":"Arch Dermatol Res"},{"key":"2024051712184643900_ljae052-B34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024051712184643900_ljae052-B35","first-page":"2707","article-title":"Inflammation meets sensitization \u2013 an explanation for spontaneous nociceptor activity?","volume":"154","author":"Rukwied","year":"2013","journal-title":"Pain (Amsterdam)"},{"key":"2024051712184643900_ljae052-B36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","article-title":"Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus","volume":"140","author":"Pogatzki-Zahn","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2024051712184643900_ljae052-B37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J Dermatol Sci"},{"key":"2024051712184643900_ljae052-B38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","article-title":"CGRP-immunoreactive nerves in prurigo nodularis \u2013 an exploration of neurogenic inflammation","volume":"27","author":"Liang","year":"2000","journal-title":"J Cutan Pathol"},{"key":"2024051712184643900_ljae052-B39","first-page":"1347","article-title":"Management of common opioid-induced adverse effects","volume":"74","author":"Swegle","year":"2006","journal-title":"Am Fam Physician"},{"key":"2024051712184643900_ljae052-B40","doi-asserted-by":"crossref","first-page":"15551","DOI":"10.1038\/s41598-018-33620-7","article-title":"Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation","volume":"8","author":"Melo","year":"2018","journal-title":"Sci Rep"},{"key":"2024051712184643900_ljae052-B41","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jid.2021.10.011","article-title":"Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans","volume":"142","author":"Sutaria","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"2024051712184643900_ljae052-B42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jaad.2023.01.042","article-title":"The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis","volume":"88","author":"Parthasarathy","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B43","doi-asserted-by":"crossref","first-page":"e111\u201312","DOI":"10.1016\/j.jaad.2022.05.014","article-title":"Understanding racial disparities in prurigo nodularis","volume":"87","author":"Sutaria","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2021.09.028","article-title":"Racial disparities in mortality among patients with prurigo nodularis: a multi-center cohort study","volume":"86","author":"Sutaria","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/medicines6040098","article-title":"Racial and gender differences in the presentation of pruritus","volume":"6","author":"Whang","year":"2019","journal-title":"Medicines"},{"key":"2024051712184643900_ljae052-B46","first-page":"30","article-title":"Pruritus in Black skin: unique molecular characteristics and clinical features","volume":"113","author":"McColl","year":"2021","journal-title":"J Natl Med Assoc"},{"key":"2024051712184643900_ljae052-B47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jdermsci.2022.02.004","article-title":"Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis","volume":"105","author":"Sutaria","year":"2022","journal-title":"J Dermatol Sci"},{"key":"2024051712184643900_ljae052-B48","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaad.2019.08.072","article-title":"Racial differences in dermatologic conditions associated with HIV: a cross-sectional study of 4679 patients in an urban tertiary care center","volume":"82","author":"Bender","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B49","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jaad.2023.06.045","article-title":"Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program","volume":"89","author":"Joel","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaad.2019.09.007","article-title":"Analysis of real-world treatment patterns in patients with prurigo nodularis","volume":"82","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B51","article-title":"Dupixent\u00ae (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis","author":"Regeneron Inc","year":"28  2022","journal-title":"PR Newswire"},{"key":"2024051712184643900_ljae052-B52","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2024051712184643900_ljae052-B53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2024051712184643900_ljae052-B54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Exp Dermatol"},{"key":"2024051712184643900_ljae052-B55","author":"Sanofi"},{"key":"2024051712184643900_ljae052-B56","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nature Med"},{"key":"2024051712184643900_ljae052-B57","author":"Sanofi and Regeneron Pharmaceuticals"},{"key":"2024051712184643900_ljae052-B58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024051712184643900_ljae052-B59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamadermatol.2023.2609","article-title":"Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab","volume":"159","author":"Deng","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024051712184643900_ljae052-B60","author":"Galderma R&D"},{"key":"2024051712184643900_ljae052-B61","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"2024051712184643900_ljae052-B62","author":"Galderma R&D"},{"key":"2024051712184643900_ljae052-B63","author":"Galderma R&D"},{"key":"2024051712184643900_ljae052-B64","author":"Galderma R&D"},{"key":"2024051712184643900_ljae052-B65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40257-020-00534-y","article-title":"Emerging therapeutic options for chronic pruritus","volume":"21","author":"Reszke","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2024051712184643900_ljae052-B66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3037","article-title":"Oncostatin M can sensitize sensory neurons in inflammatory pruritus","volume":"13","author":"Tseng","year":"2021","journal-title":"Sci Transl Med"},{"key":"2024051712184643900_ljae052-B67","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024051712184643900_ljae052-B68","author":"Kiniksa Pharmaceuticals"},{"key":"2024051712184643900_ljae052-B69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"2024051712184643900_ljae052-B70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-0560.1998.tb01718.x","article-title":"Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal","volume":"25","author":"Liang","year":"1998","journal-title":"J Cutan Pathol"},{"key":"2024051712184643900_ljae052-B71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuron.2019.01.012","article-title":"A mast-cell-specific receptor mediates neurogenic inflammation and pain","volume":"101","author":"Green","year":"2019","journal-title":"Neuron"},{"key":"2024051712184643900_ljae052-B72","author":"Proquest"},{"key":"2024051712184643900_ljae052-B73","doi-asserted-by":"crossref","first-page":"e24137","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAK-STAT"},{"key":"2024051712184643900_ljae052-B74","author":"Incyte Corporation"},{"key":"2024051712184643900_ljae052-B75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"2024051712184643900_ljae052-B76","author":"Pfizer Inc"},{"key":"2024051712184643900_ljae052-B77","author":"Incyte Corporation"},{"key":"2024051712184643900_ljae052-B78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/AJP.0000000000000211","article-title":"Nalbuphine for treatment of opioid-induced pruritus","volume":"32","author":"Jannuzzi","year":"2016","journal-title":"Clin J Pain"},{"key":"2024051712184643900_ljae052-B79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdin.2022.03.007","article-title":"Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: a review of basic science and clinical implications","volume":"7","author":"Elmariah","year":"2022","journal-title":"JAAD Int"},{"key":"2024051712184643900_ljae052-B80","author":"Trevi Therapeutics"},{"issue":"s103","key":"2024051712184643900_ljae052-B81","article-title":"Oral nalbuphine extended-release is effective in severe prurigo nodularis-associated pruritus: results from a phase 2b\/3, double-blind, placebo-controlled study","volume":"6","author":"St\u00e4nder","year":"2022","journal-title":"J Cutan Med"},{"key":"2024051712184643900_ljae052-B82","first-page":"53","article-title":"Psychiatric comorbidity in prurigo nodularis and the impact of socioeconomic status","volume":"15","author":"Han","year":"2022","journal-title":"J Clin Aesth Dermatol"},{"key":"2024051712184643900_ljae052-B83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jdv.17816","article-title":"Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase","volume":"36","author":"Weisshaar","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024051712184643900_ljae052-B84","author":"Trevi Therapeutics"},{"key":"2024051712184643900_ljae052-B85","author":"Trevi Therapeutics, Inc"},{"key":"2024051712184643900_ljae052-B86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Dermato-Venereol"},{"key":"2024051712184643900_ljae052-B87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2340\/00015555-3120","article-title":"Aprepitant in anti-histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II trial (APREPRU)","volume":"99","author":"Tsianakas","year":"2019","journal-title":"Acta Dermato-Venereol"},{"key":"2024051712184643900_ljae052-B88","author":"Vyne Therapeutics Inc"},{"key":"2024051712184643900_ljae052-B89","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024051712184643900_ljae052-B90","author":"Menlo Therapeutics Inc"},{"key":"2024051712184643900_ljae052-B91","author":"Vyne Therapeutics Inc"},{"key":"2024051712184643900_ljae052-B92","author":"Vyne Therapeutics Inc"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae052\/57096984\/ljae052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae052\/57724947\/ljae052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae052\/57724947\/ljae052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:22:40Z","timestamp":1715934160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/6\/798\/7606550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":92,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae052","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,2,12]]}}}